Cancer, as the leading cause of threats to human health, has steadily increased in incidence and mortality . With advancements in technology and medical progress, cancer treatment methods have undergone three revolutionary phases: conventional therapies, targeted therapies, and immunotherapy, with the latter heralding a new era in oncology treatment.
Immunotherapy targeting neoantigens holds great potential in cancer treatment. Tumor neoantigens are highly immunogenic and have significant potential for anti-tumor effects. These neoantigens are primarily used in the development of vaccines, including peptide vaccines, mRNA vaccines, DNA vaccines, and dendritic cell (DC) vaccines. Among them, peptide vaccines offer several key advantages: high specificity and safety; cell-independent production; low risk of autoimmunity; direct presentation of short peptides to MHC molecules; proven clinical efficacy of long peptides; strong immune-stimulating effects; and the ability to target multiple antigens.
Minkai Biomedical is dedicated to innovation and focuses on the R&D of personalized tumor neoantigen peptide vaccines. Led by world-renowned medical experts and industry investors, the company brings together a multidisciplinary team of experts, including surgeons, clinical physicians, clinical trial specialists, tumor immunologists, bioinformaticians, and computational biologists. By leveraging immunomics for precise screening and optimization of immunotherapeutic regimens, we aim at offering new therapeutic options to patients with refractory tumors.
Advanced Technology Platforms
1.IT + BT Integration: High-throughput sequencing combined with artificial intelligence, featuring core algorithms for neoantigen prediction and screening.
2. Core Patent Screening System: Selects neoantigens that can be presented by MHC I/II molecules, inducing specific TCR clonal expansion.
3. Multi-omics + Artificial Intelligence: Identifies specific companion diagnostic markers.
4.Comprehensive Immunotherapy
Minkai Biomedical’s ‘IT + BT’ model integrates high-throughput sequencing with artificial intelligence to predict neoantigens. Using its core patent screening system, it selects neoantigens that can be presented by MHC I/II molecules and induce specific TCR clonal expansion, with a neoantigen immunogenicity prediction success rate exceeding 95%.
The company possesses a GMP-grade peptide vaccine preparation, quality control, and efficacy monitoring systems. It has also established a closed-loop personalized precision diagnosis and treatment model for tumor neoantigens: 'Precision Diagnosis – Combined Therapy – Immune Monitoring.’
Strong R&D Capabilities
Minkai Biomedical’s strategic partner, the Champalimaud Foundation, is a globally renowned cancer treatment and research center. Equipped with state-of-the-art technologies, services and facilities, it is renowned for its pioneering translational medicine, personalized treatment plans, and interdisciplinary teamwork. The foundation brings together multidisciplinary expertise, focusing on the clinical research and translation of refractory tumors.
Robust Peptide Production Capacity
Leveraging the advantages of China's production capacity, Minkai Biomedical provides clinical-grade peptide vaccine formulations to global medical institutions and pharmaceutical enterprises through its proprietary technology platform that integrates bioinformatics and artificial intelligence. This creates economies of scale and builds a global supply chain. China’s peptide production cycle is 2–3 months, which is over 50% faster than Europe’s 6-month cycle.
Minkai Biomedical’s therapeutic personalized cancer peptide vaccines are currently in the pre-IND stage, targeting glioblastoma, lung cancer, prostate cancer, and other cancers. The company plans to extend its coverage to all solid tumors in the future. The pipeline is advancing with clinical trial design, patient recruitment, and Phase I trial goal planning. It is expected that the IND application will be submitted first to the European Medicines Agency (EMA) , with preparations underway for simultaneous IND submissions to the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) .
There is a large unmet clinical need in the oncology field. Minkai Biomedical will leverage its strengths to accelerate the R&D of personalized cancer peptide vaccines, offering more precise treatment options for cancer patients.
About Minkai Biomedical
Minkai Biomedical established in 2025,is a biopharmaceutical enterprise founded by leading medical experts from China and abroad and renowned industry investors.
Leveraging top-tier global biopharmaceutical R&D institutions and teams, Minkai Biomedical focuses on the research, clinical development, and commercialization of personalized peptide vaccines, delivering personalized and precise immunodiagnostic and therapeutic technologies, products, and solutions centered on peptide vaccines to cancer patients worldwide. By capitalizing on China’s robust peptide manufacturing capabilities, the company is committed to meeting the substantial demand for clinical-grade peptide vaccines and achieving global commercial reach for its cancer peptide vaccines.
About the Champalimaud Foundation
The Champalimaud Foundation is Minkai's strategic partner. Located in Lisbon, Portugal, it is a world-renowned cancer treatment and research center known for its advanced translational medicine, personalized therapies, and interdisciplinary collaboration. The Foundation is at the forefront of science, dedicated to advancing discoveries that benefit humanity and setting new standards in scientific knowledge.
The Botton-Champalimaud Center, part of the Foundation, is the world's first cancer center simultaneously dedicated to the research and treatment of refractory cancers, including pancreatic cancer. The Center brings together world-class experts across multiple disciplines, including surgery, clinical medicine, clinical trials, tumor immunology, bioinformatics, and computational biology.Equipped with state-of-the-art technologies, services, and facilities, the Center features a GMP cell preparation laboratory at the forefront in Europe and globally, research laboratories, a day hospital, a surgical center, and inpatient and intensive care facilities. By closely integrating science, clinical practice, and patient care, the Center aims to provide innovative and effective treatments for patients with refractory cancers.
Forward-Looking Statements
The information provided herein may contain forward-looking statements, including views, assumptions, expectations, estimates, forecasts, and understandings regarding future events, all of which are subject to change. These forward-looking statements are not guarantees of future performance, as the company’s development is subject to various risks and uncertainties. The company is under no obligation to update these statements. The company shall not be liable for any loss or damage arising from the failure of any forward-looking statements to materialize or prove to be inaccurate.
